Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 ...

September 16, 2024

Alphamab Oncology presented JSKN003's clinical data at ESMO Congress 2024, showing promising efficacy and safety in platinum-resistant ovarian cancer and advanced HER2-positive solid tumors, supporting further clinical exploration.

Related Clinical Trials

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Reference News

thailand-business-news.com

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 ...